Melanie Ivarsson
Corporate Officer/Principal bei MODERNA, INC.
Profil
Melanie Ivarsson is currently the Director at Loqus23 Therapeutics Ltd.
and the Chief Development Officer at Moderna, Inc. Previously, she worked as the Vice President & Head-Global Clinical Operations at Takeda Pharmaceuticals U.S.A., Inc. Dr. Ivarsson holds a doctorate from the University of Bristol and an MBA from MIT Sloan School of Management.
Aktive Positionen von Melanie Ivarsson
Unternehmen | Position | Beginn |
---|---|---|
MODERNA, INC. | Corporate Officer/Principal | 30.01.2020 |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Director/Board Member | 25.01.2022 |
Ehemalige bekannte Positionen von Melanie Ivarsson
Unternehmen | Position | Ende |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Ausbildung von Melanie Ivarsson
University of Bristol | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MODERNA, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Health Technology |